Abcellera Biologics Inc ABCL

$12.16 -0.92 (-7.03%)

Valuation

Market cap
4,182,174,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,007,246
Avg volume
4,806,240
Day's range
$11.75 – $12.91
Shares out
306,611,000
Stochastic %K
72%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

erpy Oct 30, 4:44 PM
$ABCL Call me crazy? Call me a man that loves punishment? I have foresight beyond todays shenanigans. Sit back, grab some popcorn, watch the show. Jmho.
1 replies
Stocktradesmoon Oct 30, 4:42 PM
$ABCL $ABCL Jefferies initiates coverage with $21 price target. Roger Song highlights ABCL635’s strong Phase 2 results, a $5B+ commercial opportunity, monthly dosing potential, and pipeline upside. Four recent initiations: Goldman: $13 JPM: $17 UBS: $18 Jefferies: $21 Wall Street is taking notice. 👀 Long and strong through all the FUD and volatility. Next 12 months will be epic!
0 replies
Merlintrader Oct 30, 4:08 PM
$ABCL Investor conferences (announced Oct 22): presenting at Stifel Healthcare (Nov 11) and Jefferies London Healthcare (Nov 16). Live audio webcasts and replays on the company IR site. Chart: last close $13.08 (Oct 29). Above the 20-day EMA, 50-day SMA, 200-day SMA (EMA20 $12.51, SMA50 $12.27, SMA200 $6.81). RSI(14) 55. 20-day range $11.08-$14.53. Webcasts: https://investors.abcellera.com/news/news-releases/2026/AbCellera-to-Present-at-Upcoming-Investor-Conferences-in-November-2026/default.aspx Hub: https://www.merlintrader.com/abcellera-biologics-stock-hub/
0 replies
erpy Oct 30, 4:08 PM
$ABCL Jeffries $21.X upgrade right before conferences. It just not that complicated. All the recent big money accumulation. Focus grasshoppers! Lets FCKING Go.
0 replies
erpy Oct 30, 4:03 PM
$ABCL Ok 1 more. Couldnt resist, 10 buys today. Lets go long and loyal!!! Buy fear !!
0 replies
Buying_Low_Selling_High Oct 30, 3:52 PM
$ABCL Not surprised with price action. Market weakness gives boost to bears but it can only work short term. I can understand the risk taking of bears but struggle to understand why would anyone else sell today at these levels knowing what's ahead.
0 replies
Stocktradesmoon Oct 30, 3:41 PM
$ABCL Jefferies🏁 $ABCL Buy-$21 and said--AbCellera is turning a proven antibody discovery engine into a promising clinical pipeline led by ABCL635, a monthly subq NK3R antibody for VMS. [ALPMY BAYRY LLY VERU VTGN] Ph2 4W data looks unprecedented/ best-in-class on efficacy, safety, with convenience, in a market where demand is proven with significant unmet need. 12W/ OLE data (early '27) and a Ph3 start could further de-risk ~$5B+ opp'y, with un-capped pipeline/ partnership value as call options. We initiate at Buy with a $21 PT.
0 replies
erpy Oct 30, 3:40 PM
$ABCL Ty. Im happy with my new position. Lets go loyal shareholders lets make some cash.
0 replies